BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hughes IP, Choong C, Rath S, Atkinson H, Cotterill A, Cutfield W, Hofman P, Harris M. Early cessation and non-response are important and possibly related problems in growth hormone therapy: An OZGROW analysis. Growth Horm IGF Res 2016;29:63-70. [PMID: 27179230 DOI: 10.1016/j.ghir.2016.04.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Maniatis AK, Carakushansky M, Galcheva S, Prakasam G, Fox LA, Dankovcikova A, Loftus J, Palladino AA, de los Angeles Resa M, Turich Taylor C, Dattani MT, Lebl J. Treatment Burden of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Randomized Study. Journal of the Endocrine Society 2022;6:bvac117. [DOI: 10.1210/jendso/bvac117] [Reference Citation Analysis]
2 Liang Y, Zhang C, Wei H, Du H, Zhang G, Yang Y, Zhang H, Gong H, Li P, Song F, Xu Z, He R, Zhou W, Zheng H, Sun L, Luo X. The pharmacokinetic and pharmacodynamic properties and short-term outcome of a novel once-weekly PEGylated recombinant human growth hormone for children with growth hormone deficiency. Front Endocrinol 2022;13:922304. [DOI: 10.3389/fendo.2022.922304] [Reference Citation Analysis]
3 Deal CL, Steelman J, Vlachopapadopoulou E, Stawerska R, Silverman LA, Phillip M, Kim HS, Ko C, Malievskiy O, Cara JF, Roland CL, Taylor CT, Valluri SR, Wajnrajch MP, Pastrak A, Miller BS. Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study. J Clin Endocrinol Metab 2022;107:e2717-28. [PMID: 35405011 DOI: 10.1210/clinem/dgac220] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Loftus J, Chen Y, Gupta A, Wajnrajch MP, Alvir JMJ, Silverman LA, Jhingran P, Kumar M, Prasad S. Suboptimal adherence to prescribed daily growth hormone regimen among Medicaid beneficiaries in the United States. Curr Med Res Opin 2022;:1-20. [PMID: 35477409 DOI: 10.1080/03007995.2022.2070378] [Reference Citation Analysis]
5 Bouhours-nouet N, Teinturier C. Long-acting recombinant human growth hormone in the treatment of pediatric growth hormone deficiency, how far have we got? Archives de Pédiatrie 2022;28:28/8S14-20. [DOI: 10.1016/s0929-693x(22)00038-0] [Reference Citation Analysis]
6 Ranke MB. Short and Long-Term Effects of Growth Hormone in Children and Adolescents With GH Deficiency. Front Endocrinol (Lausanne) 2021;12:720419. [PMID: 34539573 DOI: 10.3389/fendo.2021.720419] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
7 Yuen KCJ, Miller BS, Boguszewski CL, Hoffman AR. Usefulness and Potential Pitfalls of Long-Acting Growth Hormone Analogs. Front Endocrinol (Lausanne) 2021;12:637209. [PMID: 33716988 DOI: 10.3389/fendo.2021.637209] [Cited by in Crossref: 2] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
8 Yuen KCJ, Miller BS, Biller BMK. The current state of long-acting growth hormone preparations for growth hormone therapy. Curr Opin Endocrinol Diabetes Obes 2018;25:267-73. [PMID: 29746309 DOI: 10.1097/MED.0000000000000416] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
9 Rose SR. Management options for pediatric growth hormone deficiency. Expert Opinion on Orphan Drugs 2019;7:47-55. [DOI: 10.1080/21678707.2019.1564036] [Reference Citation Analysis]
10 Maghnie M, Labarta JI, Koledova E, Rohrer TR. Short Stature Diagnosis and Referral. Front Endocrinol (Lausanne) 2017;8:374. [PMID: 29375479 DOI: 10.3389/fendo.2017.00374] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
11 Abraham MB, Li D, Tang D, O'Connell SM, McKenzie F, Lim EM, Hakonarson H, Levine MA, Choong CS. Short stature and hypoparathyroidism in a child with Kenny-Caffey syndrome type 2 due to a novel mutation in FAM111A gene. Int J Pediatr Endocrinol 2017;2017:1. [PMID: 28138333 DOI: 10.1186/s13633-016-0041-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
12 Strasburger CJ, Vanuga P, Payer J, Pfeifer M, Popovic V, Bajnok L, Góth M, Olšovská V, Trejbalová L, Vadasz J, Fima E, Koren R, Amitzi L, Bidlingmaier M, Hershkovitz O, Hart G, Biller BMK. MOD-4023, a long-acting carboxy-terminal peptide-modified human growth hormone: results of a Phase 2 study in growth hormone-deficient adults. Eur J Endocrinol 2017;176:283-94. [PMID: 27932411 DOI: 10.1530/EJE-16-0748] [Cited by in Crossref: 21] [Cited by in F6Publishing: 29] [Article Influence: 3.5] [Reference Citation Analysis]
13 Rohrer TR, Horikawa R, Kappelgaard A. Growth hormone delivery devices: current features and potential for enhanced treatment adherence. Expert Opinion on Drug Delivery 2016;14:1253-64. [DOI: 10.1080/17425247.2017.1243526] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]